SEP investment 'aids Cresset to speed product development'
26 Sep 2022
UK-based drug discovery and design software developer Cresset has secured investment from Scottish Equity Partners to aid an expansion in product development and delivery of new drugs.
The firm specialises in describing molecules using in silico techniques, employed to accelerate drug discovery workflows by predicting molecular interactions and enable prioritisation of drug candidates.
Cresset said the investment would enable it to broaden its science platform and attract new talent, as well as expanding its global reach, with particular focus on the US.
CEO Dr Robert Scoffin said: “The need for new drugs is increasingly important as the world seeks to address new diseases, drug resistance and previously untreatable illnesses. Crucial in the development of new drugs is the efficiency with which new compounds are developed effectively.”
“The investment will ensure computational chemists, medicinal chemists and research managers across the world have the best tools to develop the next generation of drugs.”